II期临床-话题@MedSci

#II期临床#

478篇内容 | 2599人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524747, encodeId=5e301524e4798, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, objectType=article, longId=181869, objectId=b55d181869fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b55d181869fc, replyNumber=0, likeNumber=15, createdTime=2019-10-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b55d181869fc, moduleTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b55d181869fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524746, encodeId=dd451524e46e3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=13, createdTime=2019-10-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524745, encodeId=4fe61524e4597, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, objectType=article, longId=181811, objectId=3a1a18181105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a1a18181105, replyNumber=0, likeNumber=12, createdTime=2019-10-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a1a18181105, moduleTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a1a18181105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524744, encodeId=6a511524e4492, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=73, createdTime=2019-10-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524743, encodeId=455e1524e43f9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, objectType=article, longId=181606, objectId=fdfc181606fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdfc181606fb, replyNumber=0, likeNumber=73, createdTime=2019-10-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdfc181606fb, moduleTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdfc181606fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524742, encodeId=edfc1524e42cb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果, objectType=article, longId=181538, objectId=4e6d181538d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e6d181538d7, replyNumber=0, likeNumber=64, createdTime=2019-10-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e6d181538d7, moduleTitle=辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e6d181538d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524741, encodeId=65331524e41e2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, objectType=article, longId=180601, objectId=697618060195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697618060195, replyNumber=0, likeNumber=10, createdTime=2019-10-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697618060195, moduleTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697618060195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524740, encodeId=38831524e407b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, objectType=article, longId=180576, objectId=5f001805e6d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f001805e6d8, replyNumber=0, likeNumber=65, createdTime=2019-10-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f001805e6d8, moduleTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f001805e6d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524739, encodeId=e4d91524e3972, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展, objectType=article, longId=180575, objectId=9db31805e5fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9db31805e5fb, replyNumber=0, likeNumber=63, createdTime=2019-10-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9db31805e5fb, moduleTitle=Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9db31805e5fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524738, encodeId=a1111524e38bb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉, objectType=article, longId=180261, objectId=29ed18026114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ed18026114, replyNumber=0, likeNumber=57, createdTime=2019-10-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ed18026114, moduleTitle=NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ed18026114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524737, encodeId=aad41524e3797, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, objectType=article, longId=180178, objectId=8f301801e8b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f301801e8b0, replyNumber=0, likeNumber=60, createdTime=2019-09-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f301801e8b0, moduleTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f301801e8b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524736, encodeId=df181524e36c0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, objectType=article, longId=179755, objectId=246d1e9755d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=246d1e9755d6, replyNumber=0, likeNumber=17, createdTime=2019-09-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=246d1e9755d6, moduleTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=246d1e9755d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524735, encodeId=e8cc1524e35f5, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=13, createdTime=2019-09-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524734, encodeId=627e1524e340e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, objectType=article, longId=178786, objectId=cbc51e8786dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc51e8786dd, replyNumber=0, likeNumber=17, createdTime=2019-09-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc51e8786dd, moduleTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbc51e8786dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524733, encodeId=37f91524e339f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, objectType=article, longId=178689, objectId=11b21e8689cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11b21e8689cf, replyNumber=0, likeNumber=52, createdTime=2019-09-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11b21e8689cf, moduleTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11b21e8689cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524732, encodeId=02861524e3262, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=罗氏Xofluza作为预防性流感药物III期临床安全有效, objectType=article, longId=178688, objectId=6d301e8688c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d301e8688c1, replyNumber=0, likeNumber=70, createdTime=2019-09-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d301e8688c1, moduleTitle=罗氏Xofluza作为预防性流感药物III期临床安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d301e8688c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524731, encodeId=d5f31524e31da, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, objectType=article, longId=178245, objectId=e1fa1e8245bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fa1e8245bc, replyNumber=0, likeNumber=72, createdTime=2019-08-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fa1e8245bc, moduleTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fa1e8245bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524730, encodeId=9b231524e30c6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始, objectType=article, longId=178054, objectId=7b581e8054f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b581e8054f4, replyNumber=0, likeNumber=61, createdTime=2019-08-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b581e8054f4, moduleTitle=BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b581e8054f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524729, encodeId=4ce01524e29a3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用, objectType=article, longId=177982, objectId=e7881e798242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7881e798242, replyNumber=0, likeNumber=15, createdTime=2019-08-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7881e798242, moduleTitle=Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7881e798242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524728, encodeId=42b91524e2869, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功, objectType=article, longId=177716, objectId=cb201e7716eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb201e7716eb, replyNumber=0, likeNumber=107, createdTime=2019-08-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb201e7716eb, moduleTitle=Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb201e7716eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始

2019-10-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2019-10-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据

2019-10-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2019-10-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验

2019-10-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果

2019-10-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功

2019-10-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

SCO-101治疗转移性结直肠癌患者的II期临床试验已开始

2019-10-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展

2019-10-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉

2019-10-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功

2019-09-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019

2019-09-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2019-09-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究

2019-09-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功

2019-09-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

罗氏Xofluza作为预防性流感药物III期临床安全有效

2019-09-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功

2019-08-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始

2019-08-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用

2019-08-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功

2019-08-17

科室
- - 订阅+
  - 更多科室
工具
服务